Asia: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
China’s Rise As A Global Biopharma Innovation Hub: Navigating Trends, Opportunities, And Evolving Deal Structures
China has rapidly emerged as a dominant force in early-stage biotech innovation, challenging traditional U.S. hubs like San Francisco and Boston through faster development timelines, lower clinical trial costs, and aggressive government support. As deal volume between Western biopharma companies and Chinese biotechs surges dramatically, industry leaders must navigate the complex balance between accessing China's growing scientific contributions and managing heightened geopolitical tensions and U.S. regulato
Global Healthcare
W
WilmerHale
Article
China Revises Good Clinical Practice Rules
China's revised Good Clinical Practice for Drug Trials took effect on 1 September 2026, fundamentally reshaping the regulatory landscape for clinical trials by aligning domestic requirements with ICH E6(R3) standards. The new framework introduces streamlined regulations spanning just 54 articles across six chapters, while establishing comprehensive data governance requirements and clarifying ultimate accountability for sponsors, principal investigators, and clinical trial institutions. Companies conducting
China Healthcare
B
Buren
See more

Life Sciences, Biotechnology & Nanotechnology

Article
India's Draft Biotech Patent Guidelines: What U.S. Applicants Should Know Now
India's Patent Office has released draft biotechnology examination guidelines that fundamentally reshape how U.S. patent practitioners should approach Indian filings. With strict limits on claim amendments and new standards for diagnostics, efficacy data, and enablement, the window to optimize claims closes at PCT national-phase entry—making pre-filing strategy more critical than ever.
Global IP
BT
Barnes & Thornburg LLP
Article
China’s Rise As A Global Biopharma Innovation Hub: Navigating Trends, Opportunities, And Evolving Deal Structures
China has rapidly emerged as a dominant force in early-stage biotech innovation, challenging traditional U.S. hubs like San Francisco and Boston through faster development timelines, lower clinical trial costs, and aggressive government support. As deal volume between Western biopharma companies and Chinese biotechs surges dramatically, industry leaders must navigate the complex balance between accessing China's growing scientific contributions and managing heightened geopolitical tensions and U.S. regulato
Global Healthcare
W
WilmerHale
See more

Healthcare

Article
China Revises Good Clinical Practice Rules
China's revised Good Clinical Practice for Drug Trials took effect on 1 September 2026, fundamentally reshaping the regulatory landscape for clinical trials by aligning domestic requirements with ICH E6(R3) standards. The new framework introduces streamlined regulations spanning just 54 articles across six chapters, while establishing comprehensive data governance requirements and clarifying ultimate accountability for sponsors, principal investigators, and clinical trial institutions. Companies conducting
China Healthcare
B
Buren
Article
New Medicinal Cannabis Driving Laws In NSW
New South Wales has become the first Australian state to introduce a conditional registration scheme for medicinal cannabis patients, replacing automatic drug driving penalties with a threshold-based system. The reform requires patients to register with Transport for NSW and complete mandatory education, but questions remain about whether the new framework adequately balances road safety with patient rights.
Australia Criminal
CD
Criminal Defence Lawyers Australia
See more

Food and Drugs Law

Article
Exorbitant Pricing Of Patented Cancer Drugs: The Kerala High Court On The Government’s Power Under Section 100 Of The Patents Act In India
For a woman battling metastatic breast cancer on a retired bank employee’s pension, the cost of a single 21-day course of targeted therapy, more than Rs. 58,000, was not merely a medical burden. It raised a larger legal question: can the Government use the statutory power available to it under the Patents Act to make a patented, life-saving medicine available to patients who cannot afford its market price?
India IP
SR
S.S. Rana & Co. Advocates
Article
Suspension Is Not a Standing Penalty: Bombay High Court Clarifies Section 32(3)
The Bombay High Court examines whether food safety authorities can maintain an indefinite licence suspension after documented compliance improvements, addressing the critical distinction between precautionary regulatory powers and punitive measures. The case explores how a hotel's compliance score jumped from 69% to 97% within weeks, yet remained suspended for months through two rounds of adjudication.
India Consumer
IL
IndiaLaw LLP
See more

Latest Videos

See more